Currently director of ISREC@EPFL, Elisa was the holder of the ISREC Foundation’s professorship in translational oncology from 2014 to 2020.
This election is recognition of her commitment to excellence in biomedical research.
For more information: Elisa Oricchio and Andrew Oates elected EMBO Members – EPFL
Voici la photo à utiliser, je vous laisse la travailler pour que le format joue avec notre site.
Scientists at the University of Geneva and the CHUV (Lausanne University Hospital) have discovered that a certain set of immune cells, long considered merely auxiliary, can be reprogrammed to directly attack cancer cells. This promising breakthrough paves the way for faster and more effective personalized treatments, including for pediatric cancers.
The ISREC Foundation is proud to fund this important project, conducted jointly by Prof. Camilla Jandus, Francesco Ceppi – MD PD MERc, and Prof. George Coukos at the University of Geneva and the CHUV, the aim being to strengthen immunotherapies in the fight against cancer.
Our commitment to supporting translational research, which bridges the gap between the lab and the patient’s bedside, is fully reflected in this work.
Congratulations to the teams involved in this project, and many thanks to all who contribute to these developments! For more information: Cancer: «forgotten» cells go on the offensive – Medias – UNIGE
Find out more about our activities and the projects we support:
Link to the annual report 2024
For over six decades, we have pursued a single goal: the advancement of cancer research for the benefit of patients.
By supporting the most innovative projects, concentrating expertise and always keeping clinical impact in mind, we contribute to translating basic research into actual medical progress.
Thank you to the scientists, physicians, patrons, partners and friends who make this mission a reality.
Let us continue to push the boundaries for the future of medicine.
Congratulations to Prof. Denis Migliorini and his co-authors Nicola Vannini, Helen Carrasco Hope and Jana de Sostoa on their publication, which sheds light on the largely unexplored role of cellular aging in CAR-T therapy.
Their work highlights the influence of nicotinamide adenine dinucleotide (NAD) metabolism on CAR-T cell performance, opening up new avenues for the optimization of these treatments for elderly patients.
Prof. Migliorini dedicates his academic research to innovations in the field of oncology, and the ISREC Foundation is a proud supporter of his work through his professorship.
For more information Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure | Nature Cancer
Supports for students within the scope of the “Summer Research Program for Undergraduate Students” – EPFL School of Life Sciences, and in the “Summer Undergraduate Research Program” – Faculty of Biology and Medicine, University of Lausanne.
During eight weeks of hands-on training, the selected young biologists or physicians are given the chance to discover the world of research for the very first time. This is a rewarding experience and the opportunity to establish new contacts on an international level.
As the SUR/SRP Program celebrates its 20th anniversary, we are proud of our involvement in this undertaking and of our long-standing commitment to cultivating the talents of promising young professionals.
More information
Summer Research Program ‒ SV ‐ EPFL and About the SUR Programme UNIL
The ISREC Foundation is pleased to support the ambitious research project led by Dr. Virginie Hamel and Dr. Benita Wolf, beneficiaries of the first call for TANDEM projects in 2022. The objective of their project is to enhance the safety and precision of CAR-T cell therapies for the treatment of malignant blood disorders and, ultimately, solid tumors.
Supporting this cutting-edge research at the intersection of basic research and clinical practice aligns fully with our mission.
Congratulations to the teams involved in this work for their commitment and the progress they have already made. We are eager to follow the evolution of this promising undertaking.
Link to the scientific article: Unveiling the Molecular Architecture of T Cells and Immune Synapses with Cryo-Expansion Microscopy | bioRxiv
Congratulations to Prof. Davide Rossi at IOSI (Istituto Oncologico della Svizzera Italiana – EOC) and all the teams involved in the SAKK 34/17 trial. The results of this study have recently been published in BLOOD.
This research, supported by the ISREC Foundation, has led to the development of a new therapeutic approach for patients with relapsed or refractory chronic lymphocytic leukemia. It involves an extended initial course of ibrutinib, followed by a combination therapy with venetoclax.
This strategy leads to better tumor control, a higher rate of complete remissions and a lower risk of tumor lysis syndrome.
Read the article here: https://lnkd.in/eZ5DqxAK
In this interview, Prof. Mikaël Pittet (UNIGE/HUG), immunologist and holder of the ISREC Foundation Immuno-Oncology Chair, reviews scientific observations on the effects of a ketogenic diet on the behavior of CAR-T cells programmed to recognize and attack tumor cells.
Interview (in French): Le régime cétogène et ses capacités à lutter contre certaines maladies – rts.ch – Portail Audio
The ISREC Foundation is proud to have contributed to the research of Prof. Johanna Joyce and her team. They have published a detailed new cellular map of the tumor microenvironment in the prestigious journal Immunity. These invaluable findings advance our understanding of the cellular interactions within tumors and pave the way for novel therapeutic approaches.
Link to the article Single-cell atlas of endothelial and mural cells across primary and metastatic brain tumors: Immunity
